-
1.发明授权CRYSTALLINE FORM II OF 7-(DIMETHOXY-METHYL) CAMPTOTHECIN, ITS USE AS INTERMEDIATE AND PRODUCTS OBTAINED THEREFROM 有权7-（二甲氧基甲基）晶型II的 - 喜树碱和中间体USE THEREOF，与产品获得
公开(公告)号：EP2170900B1
公开(公告)日：2012-12-12
申请号：EP08786333.8
申请日：2008-07-22
发明人： CABRI, Walter , MARZI, Mauro , GIORGI, Fabrizio , BADALONI, Elena , ARMAROLI, Silvia , MARAZZI, Giuseppe
IPC分类号： C07D491/22
CPC分类号： C07D491/22
-
公开(公告)号：EP1951738A2
公开(公告)日：2008-08-06
申请号：EP06819722.7
申请日：2006-11-23
发明人： CERRI, Alberto , ARMAROLI, Silvia , TORRI, Marco
CPC分类号： C07J17/00
摘要： New crystalline forms of 17β-(3-Furyl)-5-βandrostane-3β,14β,17α-triol are described together with pharmaceutical composition containing the same and methods for their preparation. In particular new Forms B, C, D, E and H are here described.
-
3.发明授权NOVEL PROCESS FOR THE SYNTHESIS OF 7-CHLORO-4-(PIPERAZIN-1-YL)-QUINOLINE 有权维生素VURFAHREN ZUR SYNTHESE VON 7-氯-4-（PIPERAZIN-1-YL）-CHINOLIN
公开(公告)号：EP2718268B1
公开(公告)日：2016-12-28
申请号：EP12726414.1
申请日：2012-06-05
发明人： CABRI, Walter , CASTAGNANI, Roberto , ARMAROLI, Silvia , QUATTROCIOCCHI, Gianandrea , COLANGELI, Vincenzo
IPC分类号： C07D215/46
CPC分类号： C07D215/46
-
4.发明公开NOVEL PROCESS FOR THE SYNTHESIS OF 7-CHLORO-4-(PIPERAZIN-1-YL)-QUINOLINE 有权新工艺用于合成7-氯-4-（哌嗪-1-基） - 喹啉
公开(公告)号：EP2718268A2
公开(公告)日：2014-04-16
申请号：EP12726414.1
申请日：2012-06-05
发明人： CABRI, Walter , CASTAGNANI, Roberto , ARMAROLI, Silvia , QUATTROCIOCCHI, Gianandrea , COLANGELI, Vincenzo
IPC分类号： C07D215/46
CPC分类号： C07D215/46
摘要： The present invention provides a new process of synthesis of a polymorph of 7-chloro-4-(piperazin-1-yl)-quinoline of Formula I. Said quinoline compound is substantially pure of any impurities. The present invention further provides the use of the above-mentioned polymorph of 7-chloro-4-(piperazin-1-yl)-quinoline in the synthesis of piperaquine or one of its pharmaceutically acceptable salts.
-
5.发明授权AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS 有权氨基酸衍生物的雄甾烷和ANDROSTENEN AS药物预防心脏病CYCLE
公开(公告)号：EP2004668B1
公开(公告)日：2013-03-13
申请号：EP07727992.5
申请日：2007-04-11
发明人： CERRI, Alberto , TORRI, Marco , ARMAROLI, Silvia , BANFI, Leonardo , BIANCHI, Giuseppe , CARZANA, Giulio , FERRARI, Patrizia , MICHELETTI, Rosamaria , SPUTORE, Simona , ZAPPAVIGNA, Maria Pia
IPC分类号： C07J41/00 , C07J43/00 , A61K31/58 , A61K31/565 , A61P9/04
CPC分类号： C07J41/0038 , C07J41/0016 , C07J43/003
-
6.发明公开CRYSTALLINE FORM II OF 7-(DIMETHOXY-METHYL) CAMPTOTHECIN, ITS USE AS INTERMEDIATE AND PRODUCTS OBTAINED THEREFROM 有权7-（二甲氧基甲基）晶型II的 - 喜树碱和中间体USE THEREOF，与产品获得
公开(公告)号：EP2170900A1
公开(公告)日：2010-04-07
申请号：EP08786333.8
申请日：2008-07-22
发明人： CABRI, Walter , MARZI, Mauro , GIORGI, Fabrizio , BADALONI, Elena , ARMAROLI, Silvia , MARAZZI, Giuseppe
IPC分类号： C07D491/22
CPC分类号： C07D491/22
摘要： This invention relates to a process for preparing a crystalline form of (4S)-11-(dimethoxymethyl)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]qui-no line-3,14(4H,12H)-dione (also named 7-(dimethoxy-methyl)camptothecin). With the provision of a particular crystallization step, in appropriate way, a new crystalline form of the above compound is obtained. The process for the preparation of the polymorph Form II comprises transforming camptothecin to the corresponding 7-(dimethoxy-methyl)-camptothecin, and crystallizing it from methanol.
-
7.发明公开AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS 有权氨基酸衍生物的雄甾烷和ANDROSTENEN AS药物预防心脏病CYCLE
公开(公告)号：EP2004668A2
公开(公告)日：2008-12-24
申请号：EP07727992.5
申请日：2007-04-11
发明人： CERRI, Alberto , TORRI, Marco , ARMAROLI, Silvia , BANFI, Leonardo , BIANCHI, Giuseppe , CARZANA, Giulio , FERRARI, Patrizia , MICHELETTI, Rosamaria , SPUTORE, Simona , ZAPPAVIGNA, Maria Pia
IPC分类号： C07J41/00 , C07J43/00 , A61K31/58 , A61K31/565 , A61P9/04
CPC分类号： C07J41/0038 , C07J41/0016 , C07J43/003
摘要： Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na+, K+-ATPase. Said compounds are used for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.018 秒)
